RAPP Rapport Therapeutics Inc.

Price (delayed)

$23.76

Market cap

$1.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.16

Enterprise value

$1.34B

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 27
Highlights
Rapport Therapeutics's debt has decreased by 21% YoY and by 7% from the previous quarter
RAPP's quick ratio is down by 46% YoY but it is up by 27% QoQ
The net income has plunged by 54% YoY and by 10% from the previous quarter
Rapport Therapeutics's EPS has decreased by 40% YoY and by 4.3% from the previous quarter

Key stats

What are the main financial stats of RAPP

RAPP stock price

How has the Rapport Therapeutics stock price performed over time
Intraday
-4.27%
1 week
-8.47%
1 month
-13.82%
1 year
-5.38%
YTD
-21.69%
QTD
-29.29%

Financial performance

How have Rapport Therapeutics's revenue and profit performed over time
Revenue
$20M
Gross profit
$20M
Operating income
-$167.62M
Net income
-$150.47M
Gross margin
100%
Net margin
-752.4%
The net income has plunged by 54% YoY and by 10% from the previous quarter
Rapport Therapeutics's operating income has shrunk by 52% YoY and by 9% QoQ
Rapport Therapeutics's net margin has decreased by 10% from the previous quarter
RAPP's operating margin is down by 9% since the previous quarter

Price vs fundamentals

How does RAPP's price correlate with its fundamentals

Growth

What is Rapport Therapeutics's growth rate over time

Valuation

What is Rapport Therapeutics stock price valuation
P/E
N/A
P/B
2.91
P/S
56.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.15
Rapport Therapeutics's EPS has decreased by 40% YoY and by 4.3% from the previous quarter
Rapport Therapeutics's equity has decreased by 24% YoY and by 8% from the previous quarter
RAPP's P/B is 18% lower than its last 4 quarters average of 3.7

Efficiency

How efficient is Rapport Therapeutics business performance
Rapport Therapeutics's ROE has decreased by 19% YoY and by 17% from the previous quarter
The ROA has decreased by 17% YoY and by 16% QoQ
Rapport Therapeutics's ROS has decreased by 10% from the previous quarter
The company's return on invested capital fell by 6% QoQ

Dividends

What is RAPP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RAPP.

Financial health

How did Rapport Therapeutics financials performed over time
RAPP's quick ratio is down by 46% YoY but it is up by 27% QoQ
The current ratio has decreased by 45% YoY but it has increased by 28% from the previous quarter
Rapport Therapeutics's debt is 98% less than its equity
Rapport Therapeutics's equity has decreased by 24% YoY and by 8% from the previous quarter
Rapport Therapeutics's debt has decreased by 21% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.